Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David P Greenberg

Showing results (21-30 of 68) with videos related to

Pageof 7
Sort By:
The Pediatric Infectious Disease Journal|October 11, 2003
Regional variation in the cost effectiveness of childhood hepatitis A immunizationR Jake Jacobs, David P Greenberg, Raymond S Koff, et al.
Vaccine|September 20, 2016
Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccineCorwin A Robertson, David P Greenberg, James Hedrick, et al.
The Pediatric Infectious Disease Journal|November 6, 2018
Safety and Immunogenicity of a Full-dose, Split-virion, Inactivated, Quadrivalent Influenza Vaccine in Healthy Children 6-35 Months of Age: A Randomized Controlled Clinical TrialCorwin A Robertson, Monica Mercer, Alexandre Selmani, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 10, 2015
Regarding Primary Care Patients Who Received Influenza Vaccine at Veteran Health Administration Medical CentersMichael D Decker, Carlos A DiazGranados, Ayman Chit, et al.
Clinical and Vaccine Immunology : CVI|September 19, 2014
Safety and immunogenicity of tetanus-diphtheria-acellular pertussis vaccine administered to children 10 or 11 years of ageGary S Marshall, Vitali Pool, David P Greenberg, et al.
Expert Review of Vaccines|November 5, 2016
Fluzone® High-Dose Influenza VaccineCorwin A Robertson, Carlos A DiazGranados, Michael D Decker, et al.
The Pediatric Infectious Disease Journal|February 11, 2005
Penicillin susceptibility of pneumococcal isolates causing acute otitis media in children: seasonal variationAlejandro Hoberman, Jack L Paradise, David P Greenberg, et al.
Vaccine|September 14, 2020
Brand-specific rates of pertussis disease among Wisconsin children given 1-4 doses of pertussis Vaccine, 2010-2014James H Conway, Jeffrey P Davis, Jens C Eickhoff, et al.
Vaccine|July 28, 2015
Prevention of serious events in adults 65 years of age or older: A comparison between high-dose and standard-dose inactivated influenza vaccinesCarlos A DiazGranados, Corwin A Robertson, H Keipp Talbot, et al.
Human Vaccines & Immunotherapeutics|July 9, 2016
Post-licensure safety surveillance study of routine use of tetanus toxoid, reduced diphtheria toxoid and 5-component acellular pertussis vaccineRoger Baxter, John Hansen, Julius Timbol, et al.
Pageof 7

Showing results (21-30 of 68) with videos related to

Sort By:
Pageof 7
The Pediatric Infectious Disease Journal|October 11, 2003
Regional variation in the cost effectiveness of childhood hepatitis A immunizationR Jake Jacobs, David P Greenberg, Raymond S Koff, et al.
Vaccine|September 20, 2016
Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccineCorwin A Robertson, David P Greenberg, James Hedrick, et al.
The Pediatric Infectious Disease Journal|November 6, 2018
Safety and Immunogenicity of a Full-dose, Split-virion, Inactivated, Quadrivalent Influenza Vaccine in Healthy Children 6-35 Months of Age: A Randomized Controlled Clinical TrialCorwin A Robertson, Monica Mercer, Alexandre Selmani, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 10, 2015
Regarding Primary Care Patients Who Received Influenza Vaccine at Veteran Health Administration Medical CentersMichael D Decker, Carlos A DiazGranados, Ayman Chit, et al.
Clinical and Vaccine Immunology : CVI|September 19, 2014
Safety and immunogenicity of tetanus-diphtheria-acellular pertussis vaccine administered to children 10 or 11 years of ageGary S Marshall, Vitali Pool, David P Greenberg, et al.
Expert Review of Vaccines|November 5, 2016
Fluzone® High-Dose Influenza VaccineCorwin A Robertson, Carlos A DiazGranados, Michael D Decker, et al.
The Pediatric Infectious Disease Journal|February 11, 2005
Penicillin susceptibility of pneumococcal isolates causing acute otitis media in children: seasonal variationAlejandro Hoberman, Jack L Paradise, David P Greenberg, et al.
Vaccine|September 14, 2020
Brand-specific rates of pertussis disease among Wisconsin children given 1-4 doses of pertussis Vaccine, 2010-2014James H Conway, Jeffrey P Davis, Jens C Eickhoff, et al.
Vaccine|July 28, 2015
Prevention of serious events in adults 65 years of age or older: A comparison between high-dose and standard-dose inactivated influenza vaccinesCarlos A DiazGranados, Corwin A Robertson, H Keipp Talbot, et al.
Human Vaccines & Immunotherapeutics|July 9, 2016
Post-licensure safety surveillance study of routine use of tetanus toxoid, reduced diphtheria toxoid and 5-component acellular pertussis vaccineRoger Baxter, John Hansen, Julius Timbol, et al.
Pageof 7